Refine by
Locations
- USA
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District Of Columbia
- Florida
- Georgia (Us)
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Hepatitis Chronic Suppliers In Usa
3 companies found
based inSomerville, MASSACHUSETTS (USA)
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted ...
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when ...
based inRochester, MINNESOTA (USA)
Resoundant, Inc. is a medical technology company founded by Mayo Foundation for Medical Education and Research and is located in Rochester, MN. Resoundant is dedicated to improving patient care and diagnosis accuracy by making Magnetic Resonance ...
Magnetic Resonance Elastography (MRE) is a medical imaging technology that uses MRI and low-frequency mechanical waves to noninvasively measure the stiffness of biological tissues. MRE is an FDA-cleared upgrade for MRI systems and is currently ...
based inGaithersburg, MARYLAND (USA)
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual ...
An immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). It is designed to drive CD4+ and CD8+ T-cell responses against all HBV genotypes in patients of ...